Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)DivestmentsFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Amortizatization of Intangibles: 2018-2024

Historic Amortizatization of Intangibles for BridgeBio Pharma (BBIO) over the last 7 years, with Dec 2024 value amounting to $15.8 million.

  • BridgeBio Pharma's Amortizatization of Intangibles fell 8705.50% to -$49.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $16.1 million, marking a year-over-year increase of 203.41%. This contributed to the annual value of $15.8 million for FY2024, which is 76.97% up from last year.
  • According to the latest figures from FY2024, BridgeBio Pharma's Amortizatization of Intangibles is $15.8 million, which was up 76.97% from $8.9 million recorded in FY2023.
  • BridgeBio Pharma's 5-year Amortizatization of Intangibles high stood at $17.7 million for FY2020, and its period low was $5.8 million during FY2021.
  • For the 3-year period, BridgeBio Pharma's Amortizatization of Intangibles averaged around $11.1 million, with its median value being $8.9 million (2023).
  • Its Amortizatization of Intangibles has fluctuated over the past 5 years, first skyrocketed by 1,075.41% in 2020, then crashed by 67.33% in 2021.
  • Yearly analysis of 5 years shows BridgeBio Pharma's Amortizatization of Intangibles stood at $17.7 million in 2020, then crashed by 67.33% to $5.8 million in 2021, then skyrocketed by 47.89% to $8.6 million in 2022, then increased by 3.93% to $8.9 million in 2023, then spiked by 76.97% to $15.8 million in 2024.